Search Results
Fernando Dangond, AAN 2019 – Phase II study of first oral BTK inhibitor in multiple sclerosis
Xavier Montalban, EAN 2019 – Phase II study of first oral BTK inhibitor in multiple sclerosis
Fernando Dangond, MD, MBA: Evobrutinib for Relapsing Multiple Sclerosis
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Neurology News Network: October 20, 2018
Open-Label Extension: BTKI in Relapsing MS Over 108 Weeks
BTK Inhibition and the Future of MS Management
Toxicities With BTK Inhibitors for CLL
Exploring the Rationale, Results, and Real-World Clinical Potential of BTKi in the Management of MS
Stephen L. Hauser, MD: Fenebrutinib and BTK Inhibiton in Progressive MS
The Rise of B-Cell Therapies in Relapsing MS
Resistance to BTK Inhibitors in B-Cell Malignancies